Home›Stock Screener›Biocon›Quarterly Results

Biocon Quarterly Results for Trading Insights

In Sept 2025, Biocon (BIOCON) reported revenue ₹4,356 Cr and net profit ₹133 Cr — revenue +20.9% YoY. For annual financials, live price and key ratios, visit BIOCON company profile.

Latest Quarter Net Profit
₹133 Cr
QSept 2025
Quarterly Results

BIOCON Quarterly Results — Revenue, Profit & EPS Highlights

Biocon latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Compare with BIOCON DCF to assess whether the stock is under or overvalued.

  • Revenue of ₹4,356 Cr in Sept 2025 (-1.3% vs Mar 2025, +20.9% vs Sept 2024)
  • Net Profit of ₹133 Cr in Sept 2025 (-71.0% vs Mar 2025, +392.6% vs Sept 2024)
  • EBITDA of ₹884 Cr in Sept 2025 (-17.9% vs Mar 2025)
  • Operating Margin of 19.0% in Sept 2025 (-4.0pp vs Mar 2025)
  • Earnings Per Share of ₹0.66 in Sept 2025 (-77.1% vs Mar 2025)

Biocon Quarterly Results — Revenue, EBITDA, Net Profit & EPS

BIOCON quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.

Metric Sept 2025 Mar 2025 Jun 2025 Dec 2025 Sept 2024 QoQ YoY
Revenue (₹ Cr) 4,356 4,415 3,990 4,240 3,604 -1.3% 20.9%
Net Profit (₹ Cr) 133 459 89 -52 27 - -
EBITDA (₹ Cr) 884 1,077 797 607 699 - -
EPS (₹) 0.66 2.88 0.26 1.08 -0.13 - -
Operating Margin (%) 19.0% 23.0% 18.0% 12.0% 18.0% - -

BIOCON Share Price Trend — 1-Year Movement Across Quarterly Results

Biocon 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Analyse BIOCON ownership pattern to track promoter, FII and institutional holdings.

Profitability Ratios

Profit Margin 3.1%
EBITDA Margin 20.3%
Operating Margin 19.0%
ROE (Annual) 1.9%

Balance Sheet Highlights

Total Assets ₹58,797 Cr
Total Equity ₹27,713 Cr
Current Assets ₹16,286 Cr
Current Liabilities ₹16,751 Cr

Cash Flow Analysis

Operating Cash Flow ₹4,061 Cr
Investing Cash Flow ₹-203 Cr
Financing Cash Flow ₹-1,854 Cr
Net Cash Flow ₹2,004 Cr

Current Market Data

Current Price ₹362.25
Exchange NSE
Last Updated Apr 29, 2026

Revenue Trend (₹ Cr)

Dec 2025 4,240
Jun 2025 3,990
Mar 2025 4,415
Sept 2025 4,356

Net Profit Trend (₹ Cr)

Dec 2025 -52
Jun 2025 89
Mar 2025 459
Sept 2025 133

Operating Margin Trend (%)

Dec 2025 12.0%
Jun 2025 18.0%
Mar 2025 23.0%
Sept 2025 19.0%

BIOCON vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap

Biocon latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.

Company Latest Quarter Market Cap (₹ Cr) Price (₹) Revenue (₹ Cr) Net Profit (₹ Cr) Rev QoQ % Rev YoY % Profit Margin % P/E Ratio
Sun Pharmaceutical
Sept 2025 		₹415,924.72 Cr 1778.7 14,875 3,125 +10.8% - 21.0% 136.8
Divis Laboratories
Sept 2025 		₹171,625.44 Cr 6534.0 2,860 689 +7.1% - 24.1% 251.6
Torrent Pharmaceuti…
Sept 2025 		₹139,344.76 Cr 4231.5 3,219 591 +11.3% - 18.4% 241.2
Dr Reddys Laborator…
Sept 2025 		₹109,930.83 Cr 1329.8 9,135 1,337 +1.1% - 14.6% 82.2
Lupin
Sept 2025 		₹104,941.69 Cr 2311.4 6,921 1,485 +23.2% - 21.5% 71.4
Sector Quarterly Performance Comparison
Healthcare sector • Latest quarterly results
▲ Positive Growth
▼ Negative Growth
- No Data
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores